A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects. Subjects will be randomly assigned to UBT251 2mg-dose, 4mg-dose，6mg-dose and placebo groups. The entire trial cycle includes a 6-week screening period, a 48-week double-blind treatment period, and a 4-week follow-up period.

Timeline

Start

2025-09-30

Primary completion

2027-06-04

Completion

2027-08-31

Drugs

Indications